BioNTech reports strong H1 with $9.7-bn revenue, expects demand to grow

The German pharmaceutical company said Monday that revenue hit about 9.57 billion euros ($ 9.76 bn) in the first six months of 2022, up from nearly 7.36 billion euros in the same period a year earlier

Biontech
Test tubes are seen in front of a displayed BioNtech logo in this illustration (Reuters)
AP Berlin
2 min read Last Updated : Aug 08 2022 | 8:07 PM IST

BioNTech, which teamed with Pfizer to develop a powerful COVID-19 vaccine, has reported higher revenue and net profit in the first half of the year and expects demand to grow as it releases updated vaccines to target new omicron strains.

The German pharmaceutical company said Monday that revenue hit about 9.57 billion euros (USD 9.76 billion) in the first six months of 2022, up from nearly 7.36 billion euros in the same period a year earlier. But revenue dropped to about 3.2 billion euros in the second quarter from 5.31 billion euros in April through June of last year.

BioNTech said the dynamic nature of the pandemic has led to changes in orders and revenue but that it expects a strong end to the year. It said it plans to release revamped vaccines tailored to the latest omicron variants as early as October, which could lead to a fall booster campaign.

With our initiatives around variant-adapted COVID-19 vaccine candidates, we expect an uptake in demand in our key markets in the fourth quarter of 2022, subject to regulatory approval," Jens Holstein, chief financial officer of BioNTech, said in a press release.

Moderna, another major COVID-19 vaccine producer, also is working on updated versions of its shots to release this fall.

BioNTech expects to report revenue of 13 billion to 17 billion euros from COVID-19 vaccines this year.

The German company's net profit also was higher for the first half of the year compared with the same period of 2021 5.37 billion euros vs. 3.92 billion euros and lower for the second quarter 1.67 billion euros vs. 2.79 billion euros.

For partner Pfizer, sales of COVID-19 vaccine and treatment in the second quarter propelled the pharmaceutical giant to the largest quarterly sales in its history. It said last month that it earned USD 9.9 billion from April through June.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :OmicronPharmaceutical companiesCoronavirus Vaccine

First Published: Aug 08 2022 | 8:07 PM IST

Next Story